
## Karthik V Giridhar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9403078/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Surveillance mammography after treatment for male breast cancer. Breast Cancer Research and Treatment, 2022, 194, 693-698.	1.1	1
2	Common Considerations in Male Breast Cancer Survivors. , 2021, , 319-328.		0
3	A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. Breast Cancer Management, 2021, 10, BMT59.	0.2	2
4	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Npj Breast Cancer, 2021, 7, 131.	2.3	13
5	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer, 2020, 126, 26-36.	2.0	82
6	Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?. Expert Opinion on Drug Safety, 2020, 19, 923-926.	1.0	3
7	Reply to On the proportion of male breast cancer among all breast cancers. Cancer, 2020, 126, 2034-2035.	2.0	1
8	Available and emerging molecular markers in the clinical management of breast cancer. Expert Review of Molecular Diagnostics, 2019, 19, 919-928.	1.5	9
9	Hepatitis, Pancreatitis and Rash in a Patient With Chronic Lymphocytic Leukemia. Gastroenterology, 2019, 157, e8-e9.	0.6	4
10	Hereditary Cancer Syndromes—A Primer on Diagnosis and Management, Part 2: Gastrointestinal Cancer Syndromes. Mayo Clinic Proceedings, 2019, 94, 1099-1116.	1.4	33
11	Hereditary Cancer Syndromes—A Primer on Diagnosis and Management. Mayo Clinic Proceedings, 2019, 94, 1084-1098.	1.4	39
12	Use of Multigene Prognostic Indices to Guide Clinical Decision-Making Regarding Adjuvant Systemic Therapy. Current Breast Cancer Reports, 2018, 10, 251-261.	0.5	1
13	A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 2018, 37, 599-614.	2.7	63
14	Supplements to Help Prevent Neuropathy During Chemotherapy? A Cautionary Tale. Journal of the National Cancer Institute, 2018, 110, 551-552.	3.0	0
15	Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 431-437.	2.0	20
16	High-dose melphalan and autologous hematopoietic stem cell transplant in patientÂwith C3 glomerulonephritis associatedÂwith monoclonal gammopathy. Clinical Nephrology, 2018, 89, 291-299.	0.4	3
17	Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. Leukemia and Lymphoma, 2017, 58, 1973-1976.	0.6	28
18	Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. Mayo Clinic Proceedings, 2017, 92, 1564-1582.	1.4	35

Karthik V Giridhar

#	Article	IF	CITATIONS
19	Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. International Journal of Molecular Sciences, 2017, 18, 2326.	1.8	16
20	Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget, 2017, 8, 63703-63714.	0.8	55
21	Is microRNA expression profile in prostate cancer dependent on clinicopathologic stage or cell subtype?. Translational Cancer Research, 2016, 5, S1139-S1141.	0.4	0
22	Split Decision. Journal of General Internal Medicine, 2014, 29, 1707-1710.	1.3	0
23	A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-κB activities. Carcinogenesis, 2011, 32, 1198-1206.	1.3	29
24	Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chemical Biology, 2010, 10, 5.	1.6	75
25	Potent and Selective Disruption of Protein Kinase D Functionality by a Benzoxoloazepinolone. Journal of Biological Chemistry, 2008, 283, 33516-33526.	1.6	124